3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
17
Carcinoma, Hepatocellular
5
Neoplasms
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Liver Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uveal Melanoma
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Interventions
Cyclophosphamide
13
Prednisone
10
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
9
Doxorubicin
9
Vincristine
8
Azacitidine
6
romidepsin
5
Gemcitabine
5
Brentuximab Vedotin
5
fludarabine
4
Etoposide
4
Dexamethasone
4
pembrolizumab
3
belinostat
3
Lenalidomide
3
Biopsy
3
10-propargyl-10-deazaaminopterin
3
tazemetostat
2
ruxolitinib
2
ixazomib
2
duvelisib
2
Nivolumab
2
Bendamustine Hydrochloride
2
venetoclax
1
tislelizumab
1
thymoglobulin
1
spartalizumab
1
somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)-
1
sodium-iodide symporter
1
sintilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Peripheral
×
relatlimab
×
1 year
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled